Angiogenesis plays rate limiting roles in tumor growth and invasion. Angiogenesis inhibition has been proposed as a general strategy to fight against cancers. This book covers different therapeutic targets for angiogenesis interventions with emphasis on clinical development of antiangiogenic drugs that target antiangiogenic cascade in different forms of cancers like breast cancer, multiple myeloma, renal carcinoma, gastrointestinal, prostate and lung cancer. Surrogate predictive markers of antiangiogenic therapy in novel preclinical models recapitulating tumor microenvironment together with genomic studies are special features of this book. Gene therapy approaches with emphasis on viral vectors have been explored in preclinical model with direct and indirect angiogenesis inhibitors. Recent advances in clinical application with antiangiogenic therapy resulted in encouraging clinical results are also detailed. It includes chapters that bridge the gap between basic science and clinical application of current knowledge of cancer. Different chapters are contributed by distinguished scientists and clinicians around the world making it an important addition to the bookshelves of clinicians, academics, researchers, students and institutions.